Skip to content
HowShorted

RIGEL PHARMACEUTICALS INC short interest in 2020

In 2020, RIGEL PHARMACEUTICALS INC's disclosed short interest ran from 6.40% of shares outstanding on 15 Jan 2020 to 12.81% on 31 Dec 2020, a change of +6.41 percentage points. The year's high was 14.45% on 30 Oct 2020 and its low 5.08% on 31 Jul 2020, averaging 9.53% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 19.20 days on 15 Apr 2020. Full history: RIGEL PHARMACEUTICALS INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for RIGEL PHARMACEUTICALS INC in 2020

2020 in figures

Start of year
6.40% (15 Jan 2020)
End of year
12.81% (31 Dec 2020)
Change
+6.41 pp
High
14.45% (30 Oct 2020)
Low
5.08% (31 Jul 2020)
Average
9.53%
Highest days to cover
19.20 (15 Apr 2020)
SEC filings marked
9

Every report in 2020

RIGEL PHARMACEUTICALS INC short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 20206.40%6.31results (8-K)
31 Jan 20209.13%7.60
14 Feb 20209.34%15.20
28 Feb 20209.17%14.4510-K filed, results (8-K)
13 Mar 20209.09%10.72
31 Mar 20209.05%11.89
15 Apr 20209.11%19.20
30 Apr 20208.68%6.19
15 May 20208.74%12.0110-Q filed, results (8-K)
29 May 20208.72%11.28
15 Jun 20208.67%10.16
30 Jun 20209.01%6.29
15 Jul 20209.09%1.00
31 Jul 20205.08%1.48
14 Aug 20205.87%2.3610-Q filed, results (8-K)
31 Aug 20205.86%4.29
15 Sep 20205.88%5.29
30 Sep 202011.52%4.84
15 Oct 202012.26%11.55
30 Oct 202014.45%10.43
13 Nov 202013.88%9.9710-Q filed, results (8-K)
30 Nov 202013.48%12.03
15 Dec 202013.38%12.77
31 Dec 202012.81%6.60

See also: RIGEL PHARMACEUTICALS INC's full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.